Inactivation of the human immunodeficiency viruses (HIV‐1 and HIV‐2) during the manufacturing of placental albumin and gammaglobulins

Inactivation of the human immunodeficiency viruses (HIV‐1 and HIV‐2) during the manufacturing... A laboratory study was undertaken to verify the elimination and/or inactivation of the human immunodeficiency viruses HIV‐1 and HIV‐2 during the manufacture of placental albumin and the gammaglobulins Gamma 16 and Veinoglobuline. Nine steps of the process were selected for study. Samples of current production batches were taken at these different stages and a known quantity of virus was added. Each sample was then processed according to the production schedule for the corresponding step, and the residual viral activity was measured. In eight of nine steps, a complete viral clearance was achieved. Estimation of the cumulative infectivity reduction due to these nine steps is in the following range: >12 to 16 log10 HIV‐1 and >17 to 19 log10 HIV‐2 for Gamma 16, >9 to 13 log10 HIV‐1 and >13 to 15 log10 HIV‐2 for Veinoglobuline, and >19.7 log10 HIV‐1 and >24 log10 HIV‐2 for albumin. As many other purification steps were not included in this study, the real infectivity reduction capacity for the whole process probably exceeds these values. Nevertheless, the levels of inactivation measured clearly document a rigorous fractionation process that has a high assurance of killing or eliminating all contaminating virus. TRANSFUSION 1989;29:629–634. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Inactivation of the human immunodeficiency viruses (HIV‐1 and HIV‐2) during the manufacturing of placental albumin and gammaglobulins

Transfusion, Volume 29 (7) – Sep 1, 1989

Loading next page...
 
/lp/wiley/inactivation-of-the-human-immunodeficiency-viruses-hiv-1-and-hiv-2-b7JR79pSPc
Publisher
Wiley
Copyright
1989 AABB
ISSN
0041-1132
eISSN
1537-2995
D.O.I.
10.1046/j.1537-2995.1989.29789369683.x
Publisher site
See Article on Publisher Site

Abstract

A laboratory study was undertaken to verify the elimination and/or inactivation of the human immunodeficiency viruses HIV‐1 and HIV‐2 during the manufacture of placental albumin and the gammaglobulins Gamma 16 and Veinoglobuline. Nine steps of the process were selected for study. Samples of current production batches were taken at these different stages and a known quantity of virus was added. Each sample was then processed according to the production schedule for the corresponding step, and the residual viral activity was measured. In eight of nine steps, a complete viral clearance was achieved. Estimation of the cumulative infectivity reduction due to these nine steps is in the following range: >12 to 16 log10 HIV‐1 and >17 to 19 log10 HIV‐2 for Gamma 16, >9 to 13 log10 HIV‐1 and >13 to 15 log10 HIV‐2 for Veinoglobuline, and >19.7 log10 HIV‐1 and >24 log10 HIV‐2 for albumin. As many other purification steps were not included in this study, the real infectivity reduction capacity for the whole process probably exceeds these values. Nevertheless, the levels of inactivation measured clearly document a rigorous fractionation process that has a high assurance of killing or eliminating all contaminating virus. TRANSFUSION 1989;29:629–634.

Journal

TransfusionWiley

Published: Sep 1, 1989

References

  • Elimination of infectious retroviruses during preparation of immunoglobulins
    Mitra, Mitra; Wong, Wong; Mozen, Mozen; McDougal, McDougal; Levy, Levy
  • Inactivation of human T‐cell lymphotropic virus, type III by heat, chemicals, and irradiation
    Quinnan, Quinnan; Wells, Wells; Wittek, Wittek
  • The global distribution of human immunodeficiency virus type 2 (HIV‐2) infection
    Horsburgh, Horsburgh; Holmberg, Holmberg

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off